Hostname: page-component-76fb5796d-5g6vh Total loading time: 0 Render date: 2024-04-25T15:20:14.986Z Has data issue: false hasContentIssue false

P-524 - Treatment of Depression With Bupropion in Community Mental Health Center - Case Report

Published online by Cambridge University Press:  15 April 2020

G. Račetović*
Affiliation:
Community Mental Health Centre, Health Center, Prijedor, Bosnia-Herzegovina

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Depression as a disease of modern times is constantly growing and it is regarded as a global, medical, individual and economic problem. Special importance have major depressive episodes (first or recurrent) with resistance to pharmacotherapy with antidepressants.

Aim:

Main goal of this paper is to demonstrate the realibility of using the antidepressant with dual mechanism of action (bupropion).

Methods:

Case study of elderly female patient of CMHC Prijedor with recurrent major depressive episode from author's practice and using data from a patient's file, with follow up period of 28 weeks after the first visit at CMHC Prijedor.

Results:

After resistance on first-line pharmacotherapy (SSRI antidepressant) we achieved a positive development and progressive improvement of patient's condition with better involvement to other parts of the therapeutic process (psycho- and socio-therapy) after 4 weeks of use of bupropion in a single daily dose of 150 mg [1][2].

Conclusions:

Bupropion is a drug of choice for the treatment of major depressive episode, especially for inhibited depression, and in a single daily dose of 150 mg is antidepressant of choice for the elderly with depression [3].

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2012
Submit a response

Comments

No Comments have been published for this article.